Aptose Biosciences announces 1-for-30 reverse stock split effective Feb 26, 2025

Aptose Biosciences Inc.

Reverse stock split ratio set at 1-for-30; trading on split-adjusted basis begins Feb 26.
Post-split shares outstanding approx. 2.1M; no fractional shares issued; rounded down to whole share.
CUSIP changes to 03835T408 and ISIN to CA03835T4081 effective Feb 26.
Proportionate adjustments to outstanding equity awards, exercise prices, and equity incentive plans.
Shares continue trading on Nasdaq (APTO) and TSX (APS).

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Aptose Biosciences Inc.: Filed articles of amendment under the Canada Business Corporations Act to effect a 1-for-30 reverse stock split of common shares, effective for trading starting February 26, 2025 (effective 2025-02-18).

Change: charter amendment
Effective: 2025-02-18

Exact text from the filing

The Company’s Board of Directors determined a final ratio of 1-for-30 for the reverse stock split (the “Reverse Stock Split”) and the Company filed articles of amendment under the Canada Business Corporations Act to implement the Reverse Stock Split on February 18, 2025 and announced that the Common Shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market (“Nasdaq”) and the Toronto Stock Exchange (“TSX”) commencing upon market open on February 26, 2025 subject to final confirmation from TSX and Nasdaq.

View on SEC.gov

84 governance changes filed in the last 30 days. Browse all governance changes →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-032092

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.